Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
INOVIO Pharmaceuticals entered into an underwriting agreement for a public offering of 58,747,235 shares of common stock and 12,681,337 pre-funded warrants. The underwriters fully exercised their option to purchase an additional 10,714,285 shares, bringing expected net proceeds to approximately $80.5 million. The capital will be used to support the company's development and commercialization of DNA medicines.
Precision BioSciences provided an update on its previously announced public offering of 10,235,077 shares of common stock and 5,893,964 pre-funded warrants. The company expects the net proceeds to extend its cash runway into the fourth quarter of 2029, providing sufficient capital to fund its PBGENE-HBV and PBGENE-DMD clinical programs through key inflection points.
CKX Lands entered into a definitive investment agreement for a $1 billion equity investment led by Brad Jacobs and Jacobs Private Equity II, LLC. Upon closing, Jacobs will become Chairman and CEO, and the company will be renamed and repurposed as a standalone platform for a new multibillion-dollar venture in an industry to be determined.
Valion Bio, Inc. completed a $700,000 closing under its existing Series B Preferred Purchase Agreement with 3i, LP, issuing 700 shares of Series B Non-Voting Convertible Preferred Stock and warrants to purchase 21,539 shares of common stock. As part of the agreement, the company committed to filing a registration statement for the resale of the underlying common shares within 30 days and extended the outside date for future closings to December 9, 2027.
Third Point Private Capital Income Fund Capital Raise of $4M
Third Point Private Capital Income Fund issued and sold 160,000 Class S common shares to Delticus Opportunities Fund LLC for $4.0 million. The sale was conducted as a capital drawdown under a subscription agreement where Delticus has committed to purchase up to $15 million in common shares. Delticus is an affiliate of the Fund's investment adviser.
SPACCircle Acquisition Corp. announced that holders of the units issued in its initial public offering may elect to separately trade the underlying Class A ordinary shares, warrants, and rights starting November 10, 2026. The separated securities will trade on the Nasdaq Global Market under the symbols SCQC, SCQCW, and SCQCR, respectively.
Mangoceuticals, Inc. received written consent from its Series B Preferred Stock holder to establish a new series of 8% Series D Convertible Cumulative Preferred Stock. The company plans to offer up to 1,000,000 shares of the Series D Preferred Stock at $10.00 per share through a Regulation A offering. The Series B holder also approved an amendment to recognize the senior dividend and liquidation rights of the new Series D shares.
BioVie Inc. entered into a securities purchase agreement with an institutional investor for a $4.74 million registered direct offering and concurrent private placement. The company issued 960,000 shares and 2,002,500 pre-funded warrants at $1.60 per share/equivalent, along with 2,962,500 common warrants. Proceeds are intended for working capital and general corporate purposes.
Silo Pharma entered into securities purchase agreements with accredited investors for a private placement of 136,005 common shares and 430,661 pre-funded warrants. The offering is expected to generate approximately $815,000 in net proceeds for working capital and general corporate purposes. The company also agreed to file a registration statement for the resale of the securities within 30 days of the agreement.
American Healthcare REIT, Inc. entered into a new at-the-market (ATM) equity offering sales agreement to sell up to $1.75 billion of its common stock. This new program replaces a prior ATM facility established in February 2026, which had approximately $170.1 million remaining unsold at the time of termination. The shares may be sold from time to time through a syndicate of agents including BofA Securities, Citigroup, and Morgan Stanley.
Zenas BioPharma filed a new prospectus supplement to increase its at-the-market (ATM) offering program capacity by $200 million. This replaces a prior supplement under which the company had already sold approximately $153.2 million in common stock, leaving $46.8 million unsold from the previous authorization.
Stockholders approved the issuance of up to 12,563,309 shares of common stock upon the conversion of a convertible note and 1,000,000 shares underlying a warrant issued to U.S. Bounti, LLC. The vote satisfies NYSE compliance requirements for issuing more than 20% of the company's outstanding shares in connection with the August 2026 Purchase Agreement.
aTyr Pharma, Inc. filed a prospectus supplement to establish an at-the-market (ATM) offering program for the sale of up to $79,994,251 of its common stock. The sales will be conducted through Jefferies LLC as the sales agent under an existing Open Market Sale Agreement. This filing allows the company to raise equity capital from time to time at prevailing market prices.
Janus Living, Inc. closed a registered underwritten public offering of 30,187,500 shares of Class A-1 common stock. The offering included the full exercise of the underwriters' option to purchase an additional 3,937,500 shares. The company entered into an underwriting agreement with a syndicate led by BofA Securities, J.P. Morgan, Wells Fargo, and Goldman Sachs.
North Haven Net REIT sold approximately 2.79 million common shares in a continuous private offering for aggregate consideration of $58.6 million. The sale included Class S, Class F-I, Class I, and Class E common shares and was conducted as an unregistered sale of equity securities under Regulation D.
EQT Exeter Real Estate Income Trust Capital Raise of $920K
EQT Exeter Real Estate Income Trust, Inc. issued multiple classes of common stock in private placements to independent directors and accredited investors. The transactions included the issuance of Class E, Class A-I, and Class A-II shares for total proceeds of approximately $0.92 million, primarily through the company's distribution reinvestment plan.
Ares Real Estate Income Trust Capital Raise of $19.9M
Ares Real Estate Income Trust Inc. issued 2,396,247 shares of its Class S-PR and Class I-PR common stock in private placements exempt from registration under Regulation D. The transactions, which occurred on November 2, 2026, generated total gross proceeds of approximately $19.9 million, including activity from the company's distribution reinvestment plan.
Invesco Commercial Real Estate Finance Trust Capital Raise of $40M
Invesco Commercial Real Estate Finance Trust, Inc. sold approximately 1.6 million shares of common stock across three classes (Class S-1, Class S, and Class I) for total aggregate consideration of approximately $40.0 million. The shares were sold at prices ranging from $24.8655 to $24.9801 per share, which were based on the company's net asset value per share as of September 30, 2026. The transactions were conducted as unregistered sales of equity securities exempt from registration under Section 4(a)(2) of the Securities Act.
Warburg Pincus Access Fund, L.P. sold unregistered limited partnership units for aggregate consideration of approximately $10.0 million on October 1, 2026. The sale was part of the Fund's continuous private offering and included units sold to third-party investors and independent directors across Class B1, B3, and E units. The Fund also disclosed its Transactional NAV per unit for various classes as of September 30, 2026, to establish pricing for these transactions.
Nuveen Farmland REIT sold an aggregate of 108,848.03 common shares across multiple classes (Type A-I, A-II, S, I, and E) for total consideration of approximately $2.2 million. The transactions were conducted as part of the company's ongoing continuous private offering exempt from registration under Regulation D.
60 Degrees Pharmaceuticals entered into inducement agreements with warrant holders to exercise existing warrants for 584,492 shares at a reduced price of $0.90 per share. In exchange for the cash exercise, the company will issue new unregistered warrants for up to 1,168,984 shares. The company expects to receive gross proceeds of approximately $526,042 to be used for working capital and general corporate purposes.
Precision BioSciences priced an underwritten public offering of approximately 10.2 million shares and 5.9 million pre-funded warrants for gross proceeds of $125 million. The offering included participation from several life sciences investors including First Light Asset Management and MPM BioImpact. Proceeds will fund research and development for PBGENE-HBV and PBGENE-DMD programs.
Parabolic Technologies, Inc. closed a firm commitment underwritten public offering of 4,963,235 units at a price of $2.72 per unit, generating gross proceeds of approximately $13.5 million. Each unit consists of one share of Class A common stock (or a pre-funded warrant) and two warrants with an initial exercise price of $6.80. The company intends to use the net proceeds for working capital, general corporate purposes, and debt repayment.
Annovis Bio entered into an underwriting agreement to raise approximately $21.0 million through a public offering of 19,000,000 shares of common stock and 2,000,000 pre-funded warrants, accompanied by warrants to purchase an additional 21,000,000 shares. The company intends to use the proceeds for the clinical development of its lead compound, Buntanetap, in studies for Alzheimer’s and Parkinson’s disease.
Monroe Capital Asset-Backed Finance Company Capital Raise
Monroe Capital Asset-Backed Finance Company, LP issued 220 shares (Class-S and Class-I) and $220,000 in principal amount of 12.00% promissory notes to approximately 220 accredited investors. The company received aggregate net proceeds of $152,000 from the notes and approximately $5,592 from the equity shares. The transaction was conducted as a private placement to satisfy REIT-related administrative and capital requirements.
BHAV Acquisition Corp II completed its initial public offering of 10,000,000 units at $10.00 per unit, raising $100 million in gross proceeds. Simultaneously, the company raised an additional $2.25 million through a private placement of 225,000 units to its sponsor, BHAV Partners II LLC. A total of $100.5 million ($10.05 per unit) was placed into a trust account to fund a future business combination.
CVR Energy issued and sold 10,515,248 shares of common stock at a public offering price of $47.55 per share, generating approximately $490 million in net proceeds. The company intends to use the funds to finance its acquisition of refineries from Marathon Petroleum Corporation and to redeem its outstanding 5.750% Senior Notes due 2028.
BlackRock Monticello Debt Real Estate Investment Trust Capital Raise of $19.8M
BlackRock Monticello Debt Real Estate Investment Trust sold 783,564.3076 common shares in a continuous private offering for aggregate consideration of approximately $19.77 million. The sale included Class I, Class S, and Class E common shares and was conducted as an unregistered sale exempt under Regulation D.
Live Oak Bancshares, Inc. priced a public offering of 4,000,000 depositary shares, each representing a 1/40th interest in its 8.750% Fixed Rate Series B Non-Cumulative Perpetual Preferred Stock, at $25 per share. The company expects to raise $100 million in gross proceeds (excluding a 600,000 share overallotment option) to support balance sheet growth and enhance its capital position.
Vertical Data Inc. closed a $4.24 million private placement of 1,413,640 common shares at $3.00 per share to support a potential uplisting to a national securities exchange. The offering included significant participation from insiders, including CEO Deven Soni, and the company's placement agent, B. Riley Securities.